George Howard1, Maciej Banach2, Mary Cushman2, David C Goff2, Virginia J Howard2, Daniel T Lackland2, Jim McVay2, James F Meschia2, Paul Muntner2, Suzanne Oparil2, Melanie Rightmyer2, Herman A Taylor2. 1. From the Departments of Biostatistics (G.H.) and Epidemiology (V.J.H., P.M.), UAB School of Public Health, Birmingham, AL; Department of Hypertension, Medical University of Lodz, Lodz, Poland (M.B.); Department of Medicine, University of Vermont, Burlington (M.C.); Office of the Dean, Colorado School of Public Health, Aurora, CO (D.C.G.); Department of Neurosciences, Medical University of South Carolina, Charleston (D.T.L.); Bureau of Health Promotion and Chronic Disease, Alabama Department of Public Health, Montgomery (J.M.V., M.R.); Department of Neurology, Mayo Clinic, Jacksonville, FL (J.F.M.); Department of Medicine, UAB School of Medicine, Birmingham, AL (S.O.); and Department of Medicine, Morehouse School of Medicine, Atlanta, GA (H.A.T.). ghoward@uab.edu. 2. From the Departments of Biostatistics (G.H.) and Epidemiology (V.J.H., P.M.), UAB School of Public Health, Birmingham, AL; Department of Hypertension, Medical University of Lodz, Lodz, Poland (M.B.); Department of Medicine, University of Vermont, Burlington (M.C.); Office of the Dean, Colorado School of Public Health, Aurora, CO (D.C.G.); Department of Neurosciences, Medical University of South Carolina, Charleston (D.T.L.); Bureau of Health Promotion and Chronic Disease, Alabama Department of Public Health, Montgomery (J.M.V., M.R.); Department of Neurology, Mayo Clinic, Jacksonville, FL (J.F.M.); Department of Medicine, UAB School of Medicine, Birmingham, AL (S.O.); and Department of Medicine, Morehouse School of Medicine, Atlanta, GA (H.A.T.).
Abstract
BACKGROUND AND PURPOSE: Although pharmacological treatment of hypertension has important health benefits, it does not capture the benefit of maintenance of ideal health through the prevention or delay of hypertension. METHODS: A total of 26 875 black and white participants aged 45+ years were assessed and followed for incident stroke events. The association was assessed between incident stroke and: (1) systolic blood pressure (SBP)categorized as normal (<120 mm Hg), prehypertension (120-139 mm Hg), stage 1 hypertension (140-159 mm Hg), and stage 2 hypertension (160 mm Hg+), and (2) number of classes of antihypertensive medications, classified as none, 1, 2, or 3 or more. RESULTS: During 6.3 years of follow-up, 823 stroke events occurred. Nearly half (46%) of the population were successfully treated (SBP<140 mm Hg) hypertensives. Within blood pressure strata, the risk of stroke increased with each additional class of required antihypertensive medication, with hazard ratio [HR], 1.33; 95% confidence interval, 1.16 to 1.52 for normotensive, HR, 1.15; 95% confidence interval, 1.05 to 1.26 for prehypertension, and HR, 1.22; 95% confidence interval, 1.06 to 1.39 for stage 1 hypertension. A successfully treated (SBP<120 mm Hg) hypertensive person on 3+ antihypertensive medication classes was at marginally higher stroke risk than a person with untreated stage 1 hypertension (HR, 2.48 versus HR=2.19; relative to those with SBP <120 on no antihypertensive medications). CONCLUSIONS: Maintaining the normotensive status solely through pharmacological treatment has a profound impact, as nearly half of this general population cohort were treated to guideline (SBP<140 mm Hg) but failed to return to risk levels similar to normotensive individuals. Even with successful treatment, there is a substantial potential gain by prevention or delay of hypertension.
BACKGROUND AND PURPOSE: Although pharmacological treatment of hypertension has important health benefits, it does not capture the benefit of maintenance of ideal health through the prevention or delay of hypertension. METHODS: A total of 26 875 black and white participants aged 45+ years were assessed and followed for incident stroke events. The association was assessed between incident stroke and: (1) systolic blood pressure (SBP)categorized as normal (<120 mm Hg), prehypertension (120-139 mm Hg), stage 1 hypertension (140-159 mm Hg), and stage 2 hypertension (160 mm Hg+), and (2) number of classes of antihypertensive medications, classified as none, 1, 2, or 3 or more. RESULTS: During 6.3 years of follow-up, 823 stroke events occurred. Nearly half (46%) of the population were successfully treated (SBP<140 mm Hg) hypertensives. Within blood pressure strata, the risk of stroke increased with each additional class of required antihypertensive medication, with hazard ratio [HR], 1.33; 95% confidence interval, 1.16 to 1.52 for normotensive, HR, 1.15; 95% confidence interval, 1.05 to 1.26 for prehypertension, and HR, 1.22; 95% confidence interval, 1.06 to 1.39 for stage 1 hypertension. A successfully treated (SBP<120 mm Hg) hypertensiveperson on 3+ antihypertensive medication classes was at marginally higher stroke risk than a person with untreated stage 1 hypertension (HR, 2.48 versus HR=2.19; relative to those with SBP <120 on no antihypertensive medications). CONCLUSIONS: Maintaining the normotensive status solely through pharmacological treatment has a profound impact, as nearly half of this general population cohort were treated to guideline (SBP<140 mm Hg) but failed to return to risk levels similar to normotensive individuals. Even with successful treatment, there is a substantial potential gain by prevention or delay of hypertension.
Authors: D C Bezerra; A R Sharrett; K Matsushita; R F Gottesman; D Shibata; T H Mosley; J Coresh; M Szklo; M S Carvalho; E Selvin Journal: Neurology Date: 2011-12-14 Impact factor: 9.910
Authors: William S Weintraub; Stephen R Daniels; Lora E Burke; Barry A Franklin; David C Goff; Laura L Hayman; Donald Lloyd-Jones; Dilip K Pandey; Eduardo J Sanchez; Andrea Parsons Schram; Laurie P Whitsel Journal: Circulation Date: 2011-07-25 Impact factor: 29.690
Authors: Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard Journal: Neuroepidemiology Date: 2005-06-29 Impact factor: 3.282
Authors: Virginia J Howard; Dawn O Kleindorfer; Suzanne E Judd; Leslie A McClure; Monika M Safford; J David Rhodes; Mary Cushman; Claudia S Moy; Elsayed Z Soliman; Brett M Kissela; George Howard Journal: Ann Neurol Date: 2011-03-17 Impact factor: 10.422
Authors: Debbie A Lawlor; Lois Kim; Richard Morris; Antoinette Amuzu; Peter Whincup; Shah Ebrahim Journal: PLoS One Date: 2011-04-13 Impact factor: 3.240
Authors: N E M Jaspers; J A N Dorresteijn; Y van der Graaf; J Westerink; L J Kappelle; H M Nathoe; A Algra; F L J Visseren Journal: Int J Obes (Lond) Date: 2017-08-04 Impact factor: 5.095
Authors: Gabriel S Tajeu; John N Booth; Lisandro D Colantonio; Rebecca F Gottesman; George Howard; Daniel T Lackland; Emily C O'Brien; Suzanne Oparil; Joseph Ravenell; Monika M Safford; Samantha R Seals; Daichi Shimbo; Steven Shea; Tanya M Spruill; Rikki M Tanner; Paul Muntner Journal: Circulation Date: 2017-06-20 Impact factor: 29.690
Authors: Mercedes Sotos-Prieto; Josiemer Mattei; Frank B Hu; Andrea K Chomistek; Eric B Rimm; Walter C Willett; A Heather Eliassen; Stephanie E Chiuve Journal: Circ Cardiovasc Qual Outcomes Date: 2016-02
Authors: Kyle B Walsh; Daniel Woo; Padmini Sekar; Jennifer Osborne; Charles J Moomaw; Carl D Langefeld; Opeolu Adeoye Journal: Circulation Date: 2016-10-13 Impact factor: 29.690
Authors: Isha S Dhande; Yaming Zhu; Michael C Braun; M John Hicks; Scott E Wenderfer; Peter A Doris Journal: Physiol Genomics Date: 2016-12-23 Impact factor: 3.107
Authors: Tracy E Madsen; George Howard; Dawn O Kleindorfer; Karen L Furie; Suzanne Oparil; JoAnn E Manson; Simin Liu; Virginia J Howard Journal: Hypertension Date: 2019-08-13 Impact factor: 10.190
Authors: Paul Muntner; Marwah Abdalla; Adolfo Correa; Michael Griswold; John E Hall; Daniel W Jones; George A Mensah; Mario Sims; Daichi Shimbo; Tanya M Spruill; Katherine L Tucker; Lawrence J Appel Journal: Hypertension Date: 2017-03-20 Impact factor: 10.190
Authors: Vincent Chen; Hongyan Ning; Norrina Allen; Kiarri Kershaw; Sadiya Khan; Donald M Lloyd-Jones; John T Wilkins Journal: JAMA Cardiol Date: 2019-05-01 Impact factor: 14.676
Authors: Stephen K Williams; Joseph Ravenell; Sara Seyedali; Sam Nayef; Gbenga Ogedegbe Journal: Prog Cardiovasc Dis Date: 2016-09-29 Impact factor: 8.194
Authors: George Howard; Monika M Safford; Claudia S Moy; Virginia J Howard; Dawn O Kleindorfer; Fredrick W Unverzagt; Elsayed Z Soliman; Matthew L Flaherty; Leslie A McClure; Daniel T Lackland; Virginia G Wadley; LeaVonne Pulley; Mary Cushman Journal: J Am Geriatr Soc Date: 2016-09-26 Impact factor: 5.562